Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: ouija who wrote (902)	11/14/1998 7:57:00 PM
From: Scott H. Davis	Respond to of 1972

True, and they want to see a lot of date before approval as first line therapy. That was a big issue with ISIP & their 1st antisense submission. Great safety and efficacy data compared to any other treatment. But with a small test group (effect of Protease Inhibitors & Antiviral therapy combos has greatly lessened the number of CMV retinitis cases) the FDA would not approve a first line. But one can always hope the data will be strong enough to allow progression to 1st line testing. Scott